IL6 and cancer: Given that there are no known naturally occurring activating mutations in the STAT3 gene, aberrant activation of STAT3 in many types of cancers is primarily due to overexpression or deregulation of upstream signaling molecules such as IL-6/gp130, EGF/EGFR, JAK2, or Src [36-38].